Sebacia now has a new CEO and all of the silver photoparticle technology assets from Sienna Biopharmaceuticals.

Mr. Chuck Abraham is the new Chief Executive Officer of Sebacia, Inc.

Sebacia is preparing a targeted commercial launch of Sebacia Microparticles in the US for treatment of acne early in 2020 with plans to expand to additional territories later in the year.

In addition, Sebacia acquired all assets related to Sienna Biopharmaceuticals' SNA-001 (silver photoparticle technology). This includes all related intellectual property owned or licensed by Sienna and the 510(k) application for light hair removal which was submitted to FDA in September 2019. The acquisition of these assets enables Sebacia to resolve the outstanding patent interference litigation between The General Hospital Corporation and Sienna Biopharmaceuticals.

"This acquisition enables Sebacia to secure Sienna's silver photoparticle intellectual property, effectively resolving all existing patent conflicts with Sienna, while also establishing Sebacia as a leader in the use of microparticles and laser energy in dermatology,” says Mr. Abraham in a news release. “Consolidating the IP within Sebacia allows us to move forward and focus on making our innovative gold microparticle treatment for acne available to dermatologists and their patients and gives us an even deeper pipeline of potential additional indications."

Mr. Abraham was CEO of OraMetrix, Inc. which developed 3-D technology solutions to improve the quality and efficiency of orthodontic care.  Prior positions include leadership roles with eMerge Interactive, Nellcor Puritan Bennett, and General Electric Medical Systems. He attended Mississippi State University and received a Bachelor of Science in Biological/Biosystems Engineering.